Caris Chromoseq data collection for blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This study collects data from a special genetic test called Caris Chromoseq for people with certain blood cancers. It aims to learn more about these diseases and possibly guide better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasm (MPN).
- Your doctor must have ordered or plan to order the Caris Chromoseq test for you.
- Your doctor must have ordered other standard genetic tests (like cytogenetics, FISH, or NGS) around the same time as the Caris Chromoseq test.
- You must be willing to sign a consent form and follow study procedures.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
This study follows people who may have early, unclear blood count problems or certain genetic/immune patterns that can later lead to bone marrow failure or blood cancers. It may help doctors better understand risks over time and guide earlier care.
This study checks whether adding whole-genome sequencing (a deeper look at DNA) alongside standard genomic tests helps in evaluating myelodysplastic syndrome (MDS). It aims to see if this extra testing is useful and acceptable during routine care—especially for people newly being worked up for MDS.
This study checks whether adding whole genome sequencing (reading a person’s DNA more broadly) alongside standard genetic tests improves the diagnosis process for AML or MDS. It may help doctors decide on the best next steps when AML/MDS is suspected.
This study uses whole genome sequencing to analyze your leukemia's DNA. The goal is to find unique genetic changes that may help guide future treatments, though this study does not recommend any specific therapy.
Hear when a new Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.